Resveratrol and the Metabolic Syndrome

Inclusion Criteria:

• Age 30 - 60 year old men

• Willingness to be randomized to resveratrol or placebo.

• BMI 30-40

• Evidence of insulin resistance with one of the following:

2 hr oral glucose tolerance result =/>120mg/dl at 2hrs acanthosis nigricans, or HgA1C 5.7 - 7.9%, or FBS >/= 100 mg/dl AND at least 2 of the following: waist circumference > 102 cm triglycerides > 150 but < 500 mg/dL HDL < 40 mg/dL Pre- hypertension orhypertension: BP>120/80 mmHg but <150/90 mmHg

• Willingness to consume only study food and drink during the in-pt phases

• Willingness to avoid the use of over-the-counter medications, herbs, or supplementswithin the last 30 days.

• Willingness to avoid NSAIDS (advil, aleve, motrin, etc.) and aspirin for the entirestudy

• Willingness to avoid ingestion of any foods containing peanuts, bilberries,blueberries, cranberries, strawberries, raspberries, grapes, grape juice, cocoapowder, dark chocolate, and red wine throughout the entire study, including run-inperiod.

• Willingness to maintain weight for the duration of the study.

• Willingness not to start an exercise regime during study participation

Exclusion Criteria:

• Tobacco smoker any time within the last 3 months

• Bleeding disorder by history or by Bleeding Questionnaire results

• History, physical or EKG findings suggestive of CV disease including angina, MI, hx ofmed/surg tx of atherosclerotic heart disease, or congestive heart disease

• BP > 145/90 after 10 minutes of rest on 2 or more screening visits

• Fasting glucose > 165 mg/dL at screening

• HbA1C > 8.0 at screening

• Current use of oral hypoglycemic agents

• Chronic glucocorticosteroid use or use of oral glucocorticosteroids for 5 days withinthe last year (inhaled glucocorticosteroid use may be acceptable; this will bedetermined by the PI)

• Current use of over the counter or prescription weight loss medication

• Current use or within the last 30 days, any cholesterol lowering medications (statins,fibrates, red yeast rice, niacin).

• Hyperthyroidism or untreated hypothyroidism

• Obstructive sleep apnea, or significant symptoms suggestive of this condition.

• Current use of anticoagulants

• Known history of chronic hepatitis or liver enzymes (ALT or AST > 2.5 times the normalupper limit)

• Known HIV infection or confirmed positive test for HIV antibodies at screening

• Inflammatory bowel disease

• Active cancer (currently under treatment)

• Other medical condition that may cause significant weight loss or gain

• Chronic or acute renal disease

• Seizure disorder

• History of any psychiatric hospital admission within the last 2 years

• History of schizophrenia, psychosis, or bipolar disease

• History, physical, social or lab findings suggestive of any medical or psychologicalcondition that would, in the opinion of the PI, impact the subject's ability tosuccessfully participate in the study.

• Alcohol or drug abuse within the last 2 years

• Any medications metabolized by cytochrome p450 3A4 (CYPA3A4) (see attachment of thesemedications as an appendix)

• Any autoimmune disease (ie rheumatoid arthritis, systemic lupus erythematosis,psoriasis)

• Physical condition requiring special diet (ie celiac disease)